Kintara Therapeutics, Inc. Profile Avatar - Palmy Investing

Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targe…

Biotechnology
US, San Diego [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Kintara Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of KTRA's Analysis
CIK: 1498382 CUSIP: 49720K101 ISIN: US49720K2006 LEI: - UEI: -
Secondary Listings
KTRA has no secondary listings inside our databases.